Morning Blood Pressure Surge and the Risk of Stroke

To the Editor:

I read with great interest the important study of Kario et al\(^1\) in the March 18th issue about morning blood pressure surge and the risk of stroke. I would like to point out that the blood pressure surge does not occur solely on awakening in the morning. My colleagues and I\(^2\) as well as others\(^3\) have found that blood pressure surges also occur after the afternoon nap, also known as the siesta. As noted in the accompanying editorial, we have also described that practice of the siesta may be associated with doubled mortality in the elderly.\(^4\) More recently, two independent groups in Greece have found people in whom the siesta is prevalent and in whom a second peak of stroke corresponds to awakening from the siesta.\(^3,5\) The unaccounted-for siesta may be one cause of misclassification of dipping; another is nocturnal awakening, the siesta’s nocturnal mirror. Many older individuals such as the cohort of Kario et al,\(^1\) wake up at night, sometimes several times (especially men with prostatism). If their nocturnal awake blood pressure measurements were included in the nocturnal average, as occurs when such awakenings are not accounted for, major misclassification would occur.\(^6\) Such misclassification would bias the night’s blood pressure, lack of dipping (or extreme dipping), and the subsequent blood pressure surge on awakening. As this surge may be extremely important as pointed out by Kario et al,\(^1\) it should be appropriately evaluated. Until more precise tools are widely available, estimation by using patients’ diaries is a simple, easy, inexpensive, and universally available tool for such evaluation. Last but not least, it is well accepted by patients and increases their confidence in the analysis extracted from the little box.

Michael Bursztyn, MD
Department of Medicine
Hadassah Mount Scopus
Jerusalem, Israel


To the Editor:

We read with interest the report on morning surge of blood pressure by Kario et al\(^1\) and the editorial by Kaplan.\(^7\) For the recognition of the morning surge, the use of early morning home blood pressure measured by the patient him- or herself is suggested.\(^3\) From our own experience of ambulatory 24-hour monitoring (ABPM) and home blood pressure monitoring,\(^3\) we agree with the potential benefits of this approach.

We compared self-measured blood pressure and heart rate values with the respective values of ABPM in a group of 37 consecutively recruited hypertensives with poor blood pressure control despite antihypertensive medication (Mengden et al, unpublished data, 2000). Self-measurement of blood pressure was performed with the highly accurate Omron IC system (upper arm, oscillometric device). Patients were instructed to measure blood pressure after rising and before taking antihypertensive medication for a period of 2 weeks. As the Omron IC is a memory device with automatic storage of blood pressure/heart rate values together with the respective time of measurement, we were able to compare the trough values of self-measured home blood pressure with the respective trough values of ABPM (Spacelabs Medical 90207 recorder). We compared self-measurement (in the morning before intake of antihypertensive medication), the average of 3 ABPM recordings at the end of the dose interval (morning ABPM, trough value before intake of antihypertensive medication, measuring cycles 15 minutes), and the mean daytime readings of ABPM (6 AM to 10 PM).

The highest blood pressure values were observed with self-measurement of home blood pressure (163.0±20.0/90.2±10.1 mm Hg) as compared with morning ABPM values (151.1±20.1/88.0±10.9 mm Hg; P=0.0001 for systolic values). ABPM daytime values (148.4±14.9/89.0±9.4 mm Hg) did not differ significantly from morning ABPM values. Heart rate at the end of the dose interval was significantly lower for self-measurement as compared with ABPM readings (71.8±9.0 versus 76.9±14.6 and 77.2±12.0; P=0.01). In our patients, self-measurement delivered additional information about the early morning rise of blood pressure and heart rate that was different as compared with ABPM. The self-measured readings indicate the need for more effective, long-acting antihypertensive therapy (24-hour or longer efficacy). The significantly lower heart rate observed with self-measurement despite higher blood pressure values may indicate that activation of the sympathetic nervous system played a minor role in the morning surge.

Home measurements can be used to recognize the morning surge of blood pressure. Given the well-known observer bias for the reporting of self-measured values, memory-equipped devices should be used to identify the exact measurement time with regard to rising and medication intake.\(^4\)

Thomas Mengden, MD
Sakir Uen, MD
Hans Vetter, MD
Department of Internal Medicine
University Clinic
Bonn, Germany
mengden@uni-bonn.de


To the Editor:

Kario et al\(^1\) report that a higher morning blood pressure surge (MBPS) is associated with stroke risk independent of ambulatory blood pressure (BP), nocturnal BP falls, and silent infarct in older hypertensives. The authors suppose that an excessive MBPS might trigger strokes through some hemodynamic mechanism such as increased shear stress on the atherosclerotic cerebral vessels, but there are several other factors that change during the morning hours. These include an increase of sympathetic nervous activity, particularly α-adrenergic activity,\(^2\) and other related acute risk factors such as platelet hyperactivity, hypercoagulability and hypofibrinolysis, blood viscosity, and increased vas-
cular spasm. We have recently reported that in never-treated subjects with essential hypertension, a rise in systolic BP ≥50 mm Hg and/or diastolic BP ≥22 mm Hg during the early morning (6:00 to 10:00 AM) is associated with the highest morning values of the ratio between low-frequency and high-frequency RR interval (considered as a marker of sympathetic overactivity), increased urinary catecholamine output, and left ventricular hypertrophy. The coexistence of sympathetic overactivity and left ventricular hypertrophy in patients with higher MBPS might contribute to their raised vascular risk and might explain the increase of cardiovascular accidents in early morning. The increase of sympathetic activity in the early morning is associated with some adverse modifications regarding heart rate, fibrinolytic activity, and platelet aggregability that may make the morning BP rise at most a pathophysiological cofactor in the determination of the increased morning rate of cardiovascular morbidity and fatal events.

Raffaele Marfella, MD, PhD
Katherine Esposito, MD, PhD
Pasquale Gualdiéro, MD, PhD
Dario Guigliano, MD, PhD
Department of Geriatrics and Metabolic Diseases
Second University of Naples
Napoli, Italy
raffaele.marfella@unina2.it

Response
Dr Burszytyn pointed out that individual behavioral factors such as a siesta and nocturnal awaking are important modulators of the association between morning blood pressure (BP) surge and cardiovascular risk. Recently developed ambulatory BP monitors (ABPM) equipped with actigraphy could be used to assess the relationships between the morning- or siesta-associated BP surges and changes in physical activity.

Dr Mengden et al recommended using memory-equipped devices for self-measurement of morning BP (SMBP) to reduce the effects of this response, the second measurement may be preferable to assess morning BPs. SMBP cannot directly assess the morning BP surge, but when evening BPs measured just before going to bed are combined with morning BPs, some additional information can be derived for clinical practice. We analyzed data from the same 519 patients using the morning and evening BPs (ME) derived from the ABPM data, after controlling for baseline characteristics, both the ME average (morning systolic BP + evening systolic BP / 2) (10 mm Hg increase; relative risk = 1.41 [95% CI = 1.19 to 1.67], P = 0.0001) and the ME surge (morning systolic BP – evening systolic BP) (10 mm Hg increase; relative risk = 1.24 [95% CI = 1.08 to 1.42], P = 0.0025) were independently associated with the risk of stroke.

We agree with the opinion of Dr Marfella et al that other sympathetic activation–associated potentiation of risk factors, including heart rate and platelet/hemostatic factors, would augment the morning risk for cardiovascular events. In fact, in our recent study, the morning increase in platelet aggregation and in the plasma levels of von Willebrand factor and tissue-type plasminogen activator, 2 in vivo markers of endothelial cell stimulation, were significantly correlated with a higher morning BP surge in hypertensive patients (K. Kario MD, et al, Linkage between morning surge in blood pressure and acute risk factors for silent cerebrovascular disease in elderly hypertension, submitted for publication). To clarify the impact of morning BP surge from other confounders, we have just initiated the Japan Morning Surge-1 (JMS-1) Study, a randomized parallel control study, in which we attempt to study the effect of suppression of morning BP surge on target organ damage in treated hypertensives with high morning BPs.

We believe that the strict control of morning BP as well as morning-potentiated risk factors would achieve more effective prevention of cardiovascular events in hypertensive patients.

K. Kario, MD
Y. Umeda, MD
S. Hoshide, MD
Y. Hoshide, MD
M. Morinari, MD
M. Murata, MD
T. Kuroda, MD
K. Shimada, MD
Department of Cardiology
Jichi Medical School
Tochigi, Japan

T.G. Pickering, MD
The Zena and Michael A. Weiner Cardiovascular Center
Mount Sinai School of Medicine
New York, NY

J.E. Schwartz, PhD
Department of Psychiatry and Behavioral Science
State University of New York at Stony Brook
Stony Brook, NY

Effect of the Asp\textsuperscript{298} Variant of Endothelial Nitric Oxide Synthase on Survival for Patients With Congestive Heart Failure

To the Editor:

McNamara et al\textsuperscript{1} recently reported a significant association between the Asp\textsuperscript{298} variant of endothelial NO synthase (NOS3) and poorer event-free survival in congestive heart failure (CHF) patients. This study was based on the premise that the Asp\textsuperscript{298} NOS3 variant would have a shorter half-life, thus implying a decreased in vivo generation of NO, which is deemed to play a protective role. To support their contention, the authors quoted a study that claimed the Asp\textsuperscript{298} variant to be more vulnerable to intracellular cleavage.\textsuperscript{2} However, this contention was subsequently disputed by a painstaking study that clearly demonstrated that the intracellular cleavage found in cells harboring the Asp\textsuperscript{298} NOS3 substitution was an in vitro artifact\textsuperscript{3} caused by the acidic pH used.\textsuperscript{2} According to both studies, the Asp\textsuperscript{298} replacement does not affect NOS3 biological activity.\textsuperscript{2,3}

Thus, it remains controversial whether the Asp\textsuperscript{298} variant implies a blunted NOS3 activity; accordingly, the contention that the latter accounts for the poorer event-free survival in CHF observed by McNamara et al\textsuperscript{1} cannot be taken for granted. At variance with the Asp\textsuperscript{298} variant, another single-nucleotide polymorphism located in the promoter region of the NOS3 gene, the T\textsuperscript{786}C was shown to bear functional consequences. The C\textsuperscript{786} allele binds a replication protein A1 that acts as a repressor of NOS3 transcription. Therefore, it is not surprising that this allele has been associated with a significant reduction in NOS3 gene promoter activity, with ensuing reduction in the rate of transcription of NOS3 in response to hypoxia and also with vasospastic angina in Japanese patients.\textsuperscript{4}

We recently reported that the Asp\textsuperscript{298} NOS3 variant was in linkage disequilibrium with the T\textsuperscript{786}C substitution.\textsuperscript{4} More importantly, we also showed that this variant, and not the Asp\textsuperscript{298} was associated with a blunted forearm blood flow response to acetylcholine in essential hypertensive patients\textsuperscript{5} and with multivessel coronary artery disease in the GENICA study.\textsuperscript{4} Therefore, we propose that the C\textsuperscript{786} variant, which was not determined in the study by McNamara et al,\textsuperscript{1} can be the most relevant one, both functionally and as predictor of events in CHF patients.

Giuseppe Maiolino, MD
Gian Paolo Rossi, MD
Department of Internal and Experimental Medicine
University of Padova, Italy
gianpaolo.rossi@unipd.it


Response

We appreciate the point emphasized by Drs Maiolino and Rossi that other common polymorphisms exist in the NOS3 gene, including the T\textsuperscript{786}C promoter polymorphism referenced in their recent studies. We also agree that there is much debate about the functional significance of both the T\textsuperscript{786}C and the Asp\textsuperscript{298}Glu polymorphisms. Overall, clinical studies of these polymorphisms support the concept that genetic heterogeneity at the NOS3 locus influences both cardiovascular risk and clinical outcomes. Whether these specific mutations are causative, or in linkage disequilibrium with distinct and functionally more important polymorphisms, remains open to question.

Although not part of the published study, the impact of the T\textsuperscript{786}C polymorphism for heart failure outcomes has been investigated by M.B. in our laboratory. Although this analysis does confirm linkage disequilibrium between these 2 polymorphisms, the T\textsuperscript{786}C polymorphism does not appear to influence event-free survival. We cannot exclude the possibility raised by Drs Maiolino and Rossi that the impact of the Asp\textsuperscript{298} variant in our cohort was due to linkage to an additional polymorphism of NOS3. However, our data do not support the influential role for the T\textsuperscript{786}C polymorphism that they have proposed.

Dennis M. McNamara, MD
Maninder Bedi, MD
Richard Holubkov, PhD
Lisa Postava, MBA
Ravi Ramani, MD
Karen Janosko, MSN
Michael Mathier, MD
Guy A. MacGowan, MD
Srinivas Murali, MD
Arthur M. Feldman, MD, PhD
Barry London, MD, PhD
Heart Failure Section
University of Pittsburgh Medical Center
Cardiovascular Institute
Pittsburgh, Pa
Effect of the Asp298 Variant of Endothelial Nitric Oxide Synthase on Survival for Patients With Congestive Heart Failure
Giuseppe Maiolino and Gian Paolo Rossi

Circulation. 2003;108:e112
doi: 10.1161/01.CIR.000093733.09510.B2

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/108/15/e112

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/